Second Affiliated Hospital, Zhejiang University, School of Medicine
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female, age 18-70 years.
Completed radical breast cancer surgery with confirmed pathology suggested primary invasive breast adenocarcinoma, ER and/or PR positive (defined as positive cells \>1%) and HER2 negative (defined as HER2 immunohistochemistry 2+ or less and FISH negative).
Definition of high-risk factors: 4 or more positive axillary lymph nodes; 1-3 positive axillary lymph nodes with primary tumor ≥ 5 cm or histologic grade 3 or ki67 ≥ 20%; or residual lesions despite neoadjuvant chemotherapy.
No prior treatment for present breast cancer onset.
ECOG physical status score 0 to 1
Hematological examination before treatment should meet: white blood cell count (WBC) ≥ 4.0×10\^9/L, neutrophil count (ANC) ≥ 1.5×10\^9/L, platelet count (PLT) ≥ 100×10\^9/L; hemoglobin (Hb) ≥ 90g/L; AST (sGOT), ALT (sGPT) ≤ 1.5 times the normal value upper limit, creatinine ≤ 1.5 times the upper limit of normal value, total bilirubin ≤ 1.5 times the upper limit of normal value.
No serious impairment of heart, liver, kidney and other important organ functions.
You may not be if
Unwilling or unable to use an acceptable method of contraception for up to and including 8 weeks after the final dose of the test drug.
Women during pregnancy and breastfeeding after pregnancy.
Women with proven distant metastases of breast cancer.
Patients with proven sensory or motor nerve disease.
Definite cardiovascular disease, severe co-morbidity or active infection, including known HIV infection.
Patients who need long-term anticoagulant drugs for cardiovascular or thrombotic diseases.
History of other tumors.
Allergic to the study drug or its excipients, etc.
Clareo Health | Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
